Patents by Inventor Gary Bassell

Gary Bassell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of conditions associated with myotonic dystrophy
    Patent number: 11529358
    Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 20, 2022
    Assignees: Emory University, University of Florida Research Foundation, Inc.
    Inventors: Gary Bassell, Andrew Jenkins, David B. Rye, Maurice Scott Swanson, Eric Tzy-Shi Wang, Lyndon Lien
  • TREATMENT OF CONDITIONS ASSOCIATED WITH MYOTONIC DYSTROPHY
    Publication number: 20210023091
    Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
    Type: Application
    Filed: May 10, 2018
    Publication date: January 28, 2021
    Inventors: Gary BASSELL, Andrew JENKINS, David B. RYE, Maurice Scott SWANSON, Eric Tzy-Shi WANG, Lyndon LIEN
  • FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO
    Publication number: 20120231015
    Abstract: The invention relates to fragile X mental retardation protein (FMKP), compositions, and methods related thereto. In certain embodiments, the invention relates to treating a neurological disorder by administering a P13K antagonist to a subject in need thereof. In other embodiments, the invention relates to methods of diagnosing neurological disorders.
    Type: Application
    Filed: November 4, 2010
    Publication date: September 13, 2012
    Applicant: EMORY UNIVERSITY
    Inventors: Gary Bassell, Stephen Warren, Christina Gross